MIRA Pharmaceuticals (MIRA) Competitors $0.86 -0.04 (-3.89%) As of 11:14 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MIRA vs. RANI, CABA, VTGN, HLVX, ADAG, EXOZ, AVTX, JSPR, CLSD, and PYRGFShould you be buying MIRA Pharmaceuticals stock or one of its competitors? The main competitors of MIRA Pharmaceuticals include Rani Therapeutics (RANI), Cabaletta Bio (CABA), Vistagen Therapeutics (VTGN), HilleVax (HLVX), Adagene (ADAG), Exozymes (EXOZ), Avalo Therapeutics (AVTX), Jasper Therapeutics (JSPR), Clearside Biomedical (CLSD), and PyroGenesis Canada (PYRGF). These companies are all part of the "pharmaceutical products" industry. MIRA Pharmaceuticals vs. Rani Therapeutics Cabaletta Bio Vistagen Therapeutics HilleVax Adagene Exozymes Avalo Therapeutics Jasper Therapeutics Clearside Biomedical PyroGenesis Canada MIRA Pharmaceuticals (NASDAQ:MIRA) and Rani Therapeutics (NASDAQ:RANI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, valuation, profitability, earnings, risk, analyst recommendations, institutional ownership, media sentiment and dividends. Do analysts prefer MIRA or RANI? MIRA Pharmaceuticals currently has a consensus price target of $14.00, suggesting a potential upside of 1,518.50%. Rani Therapeutics has a consensus price target of $12.33, suggesting a potential upside of 902.71%. Given MIRA Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe MIRA Pharmaceuticals is more favorable than Rani Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MIRA Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Rani Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Does the media refer more to MIRA or RANI? In the previous week, Rani Therapeutics had 10 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 17 mentions for Rani Therapeutics and 7 mentions for MIRA Pharmaceuticals. MIRA Pharmaceuticals' average media sentiment score of 0.83 beat Rani Therapeutics' score of 0.27 indicating that MIRA Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MIRA Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rani Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals have more ownership in MIRA or RANI? 35.2% of MIRA Pharmaceuticals shares are held by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are held by institutional investors. 6.7% of MIRA Pharmaceuticals shares are held by insiders. Comparatively, 53.3% of Rani Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community favor MIRA or RANI? Rani Therapeutics received 31 more outperform votes than MIRA Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave MIRA Pharmaceuticals an outperform vote while only 82.93% of users gave Rani Therapeutics an outperform vote. CompanyUnderperformOutperformMIRA PharmaceuticalsOutperform Votes3100.00% Underperform VotesNo VotesRani TherapeuticsOutperform Votes3482.93% Underperform Votes717.07% Which has more risk & volatility, MIRA or RANI? MIRA Pharmaceuticals has a beta of 2.05, suggesting that its stock price is 105% more volatile than the S&P 500. Comparatively, Rani Therapeutics has a beta of 0.14, suggesting that its stock price is 86% less volatile than the S&P 500. Which has stronger earnings & valuation, MIRA or RANI? MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMIRA PharmaceuticalsN/AN/A-$11.98M-$0.52-1.66Rani TherapeuticsN/AN/A-$33.97M-$1.06-1.16 Is MIRA or RANI more profitable? Rani Therapeutics' return on equity of -219.64% beat MIRA Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets MIRA PharmaceuticalsN/A -337.44% -280.58% Rani Therapeutics N/A -219.64%-56.71% SummaryMIRA Pharmaceuticals beats Rani Therapeutics on 8 of the 15 factors compared between the two stocks. Remove Ads Get MIRA Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MIRA vs. The Competition Export to ExcelMetricMIRA PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$14.56M$6.51B$5.38B$7.14BDividend YieldN/A2.85%4.87%4.05%P/E Ratio-1.556.7722.8217.35Price / SalesN/A188.62353.9684.30Price / CashN/A65.6738.1634.64Price / Book2.885.636.263.78Net Income-$11.98M$142.37M$3.21B$247.18M7 Day Performance-18.40%-11.25%-7.92%-7.74%1 Month Performance-6.99%-14.25%-2.85%-10.35%1 Year Performance-15.20%-18.14%3.82%-7.76% MIRA Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MIRAMIRA Pharmaceuticals2.0747 of 5 stars$0.87-3.9%$14.00+1,518.5%-15.9%$14.56MN/A-1.552Earnings ReportUpcoming EarningsAnalyst RevisionGap UpRANIRani Therapeutics2.6484 of 5 stars$1.47-5.2%$12.33+739.0%-60.7%$84.22MN/A-1.39110Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageGap DownCABACabaletta Bio2.6693 of 5 stars$1.72-1.1%$22.71+1,220.6%-92.8%$84.07MN/A-0.8050Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageVTGNVistagen Therapeutics1.0655 of 5 stars$2.91+4.3%N/A-57.6%$83.99M$698,000.00-1.9740HLVXHilleVax2.4421 of 5 stars$1.68flat$3.00+78.6%-90.2%$83.67MN/A-0.5420Earnings ReportAnalyst RevisionNews CoverageGap DownADAGAdagene1.8984 of 5 stars$1.77+5.0%$8.00+352.0%-43.7%$83.39M$815,746.000.00260Analyst ForecastGap DownHigh Trading VolumeEXOZExozymesN/A$13.11-11.5%N/AN/A$81.96MN/A0.0029Gap UpAVTXAvalo Therapeutics3.0506 of 5 stars$7.63-0.4%$35.33+363.1%-59.6%$79.31M$820,000.000.0040JSPRJasper Therapeutics2.7298 of 5 stars$5.24+0.6%$62.50+1,092.7%-85.2%$78.72MN/A-1.1120Positive NewsCLSDClearside Biomedical2.2403 of 5 stars$1.03+2.5%$5.75+458.3%-37.1%$78.12M$7.70M-2.2930Analyst RevisionGap DownPYRGFPyroGenesis CanadaN/A$0.40+2.5%N/A+11.5%$75.59M$9.14M-6.7590High Trading Volume Remove Ads Related Companies and Tools Related Companies Rani Therapeutics Competitors Cabaletta Bio Competitors Vistagen Therapeutics Competitors HilleVax Competitors Adagene Competitors Exozymes Competitors Avalo Therapeutics Competitors Jasper Therapeutics Competitors Clearside Biomedical Competitors PyroGenesis Canada Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MIRA) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MIRA Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MIRA Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
